AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Geron Corp
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG001S6TSX4
1.12▼ 0.01 (-0.88%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
Financial Highlights
Revenue (TTM)
—
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
Trading Information
Previous Close
1.13
Day's Range
1.08 – 1.15
52-Week Range
1.04 – 2.01
Volume
11.2M
Avg Volume
7.4M
Share Statistics
Shares Outstanding
Employees
258
Exchange
XNAS
Listed
1996-07-31
Share count as of July 31, 2026

Geron Corp (GERN) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Geron Corp (GERN)
What is Geron Corp's Market Cap?
Geron Corp's Market Cap is $719.6M, based on as-reported figures from SEC (XBRL) filings.
What is Geron Corp's Enterprise Value?
Geron Corp's Enterprise Value is $777.1M, based on as-reported figures from SEC (XBRL) filings.
What is Geron Corp's EV / EBITDA?
Geron Corp's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Geron Corp's Net Income (TTM)?
Geron Corp's Net Income (TTM) is -$67.6M, based on as-reported figures from SEC (XBRL) filings.
What is Geron Corp's EBITDA?
Geron Corp's EBITDA is -$51.3M, based on as-reported figures from SEC (XBRL) filings.
What is Geron Corp's Diluted EPS (TTM)?
Geron Corp's Diluted EPS (TTM) is -0.11, based on as-reported figures from SEC (XBRL) filings.
What is Geron Corp's Net Debt?
Geron Corp's Net Debt is $57.5M, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · GERNAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenues:
Total revenues—
YoY growth+17.2%+30.9%—+67.1%
Costs and operating expenses:
Cost of goods sold
Research and development
Selling, general and administrative
Restructuring charges——
Total costs and operating expenses
% of revenue121.7%99.7%—129.4%
Loss from operations
% of revenue-21.7%0.3%—-29.4%
Interest income
Interest expense
Other income (expense), net
Net loss
% of revenue-29.0%-7.0%—-39.0%
Basic net loss per share (in dollars per share)
Diluted net loss per share (in dollars per share)